Heineken has done the math on Ozempic, and it isn't flattering for the pub industry. The world's second-largest brewer sent a presentation to British bars and pubs earlier this month warning that the boom in GLP-1 drugs (the class of weight-loss medications that includes Ozempic and Wegovy) could shrink both the number of drinks ordered and the number of people walking through the door in the first place.

The document, revealed by Reuters, named a specific cultural casualty: the multi-pint session. Heineken said that kind of evening, a cornerstone of British pub life, could become a less frequent occurrence as more drinkers arrive on medication that dulls appetite and, apparently, the desire for alcohol alongside it.

Why a brewer is sounding this alarm

The numbers behind the warning are real. According to JP Morgan research cited by Heineken, 10 million Americans turned to GLP-1 medication last year. The UK market is smaller but growing fast. And Heineken's own consumer research says users aren't simply swapping beer for sparkling water. They are shifting toward smaller pours, lower-alcohol options, and more premium products, drinking less but spending more carefully per drink.

That last point is the tension at the heart of this story. British pubs took in nearly £14 billion in beer sales in the year to February 2026. Of that, less than £300 million came from no- and low-alcohol products. If a meaningful share of customers start behaving like GLP-1 users, even a modest shift in drinking volume would move that ratio and put serious pressure on pub revenues.

Heineken's advice to its hospitality customers: get ahead of it. Promote half pints. Stock more low- and zero-alcohol options. Pair drinks with small plates of food to give customers a reason to stay longer even if they're drinking less.

The industry is not unified on how worried to be. Diageo, which makes Guinness, told investors that any impact from weight-loss drugs going mainstream should be manageable. Carlsberg told Reuters that its data simply doesn't show GLP-1 use affecting beer consumption trends. But surveys from research firms including Circana, NIQ, and KAM have all pointed in the same direction: people on these drugs are drinking less.

What this means beyond the pub

The deeper story here is that GLP-1 drugs are doing something no public health campaign has managed at scale: changing consumption habits without requiring willpower. If 10 million Americans are already on these medications and that number keeps rising, the effect won't stay confined to waistlines. It will show up in what people eat, drink, and buy, and in the revenues of the industries built around those habits.

For UK pubs specifically, this lands on top of an already difficult decade. Pubs have been squeezed by rising energy costs, post-pandemic debt, and changing social habits among younger drinkers who were already drinking less than previous generations before Ozempic existed.

Heineken's presentation is a brewer trying to stay ahead of a structural shift rather than react to it after the fact. Whether the multi-pint session genuinely fades into a historical curiosity will depend on how fast GLP-1 adoption spreads in Britain and whether the drinking habits of users actually stick when they stop or reduce the medication. Heineken says it will keep monitoring through 2027. UK pubs probably don't have the luxury of waiting that long.